Liquidia Technologies is trading 4.3% up at $35.40 on October 15, following a settlement allowing uninterrupted YUTREPIA sales for pulmonary arterial hypertension (PAH). - On October 14, shares gained 26.59% to $33.94. - The October 13 global settlement resolved six lawsuits. Liquidia will pay $380.7 million across 2026 and 2027, remove the PH-ILD indication, and not appeal the court ruling. - No separate October 15 announcement was found.